TWIST1 induces phenotypic switching of vascular smooth muscle cells by downregulating p68 and microRNA-143/145

Jing Zhang¹, Jie-Ru Guo¹, Xian-Li Wu¹, Xia Wang¹, Zhi-Ming Zhu², Yong Wang³, Xia Gu⁴ and Ye Fan¹

¹ Department of Respiratory Disease, Xinqiao Hospital, Third Military Medical University, Chongqing, China
² Department of Hypertension and Endocrinology, Daping Hospital, Third Military Medical University, Chongqing, China
³ Department of Cardiovascular Surgery, Xinqiao Hospital, Third Military Medical University, Chongqing, China
⁴ Department of Pathology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

Keywords
microRNA-143/145; p68; phenotypic switching; TWIST1; vascular smooth muscle cell

Correspondence
Y. Fan, Department of Respiratory Disease, Xinqiao Hospital, Third Military Medical University, Chongqing, China. E-mail: fan_ye_sat@hotmail.com
Y. Wang, Department of Cardiovascular Surgery, Xinqiao Hospital, Third Military Medical University, Chongqing, China. E-mail: lizhang18@outlook.com
X. Gu, Department of Pathology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. E-mail: fygan2007@163.com

(Received 27 November 2020, accepted 4 January 2021)
doi:10.1002/2211-5463.13092

Smooth muscle cells (SMCs) are the major component of vascular wall, which play a crucial role in a great variety of arterial diseases. Different from terminally differentiated cells, SMCs possess apparent plasticity that allows their transition in response to environmental stimuli, which is characterized by alternations in protein expression, morphology, and biological behavior [1]. In normal condition, mature SMCs have a differentiated/contractile phenotype, characterized by the expression of a unique repertoire of contractile proteins, such as smooth muscle myosin heavy chain (SMMHC), alpha-smooth muscle actin (SMA), calponin, and tagln. These cells are elongated and display spindle-shape morphology. However, SMCs could undergo phenotypic switching to a dedifferentiated/synthetic state when subjected to multiple stimulation.

Abbreviations
BSA, bovine serum albumin; DAPI, 4’,6-diamidino-2-phenylindole; FBS, fetal bovine serum; GFP, green fluorescence protein; PCR, real-time polymerase chain reaction; PDGF, platelet-derived growth factor; PVDF, polyvinylidene difluoride membrane; siRNA, specific small interfering RNA; SMA, alpha-smooth muscle actin; SMC, smooth muscle cell; SMMHC, smooth muscle myosin heavy chain.
The process is characterized by decreased expression of smooth muscle markers, enhanced SMC proliferation, altered cellular function, and changed shape from spindle-like to polygonal. Pathological SMC transition is a fundamental process for the development of various cardiovascular disorders, such as atherosclerosis, aneurysm, and hypertension [2–4]. Despite its essentiality in vascular regulation, the molecular mechanisms underlying SMC phenotypic switching remain incompletely understood.

TWIST1 is a basic helix-loop-helix transcription factor implicated in cell lineage determination and differentiation. Mutation or abnormal expression of TWIST1 gene is closely associated with several diseases, such as breast cancer, Sézary syndrome, and Chotzen syndrome [5,6]. Notably, recent reports have suggested a potential role of TWIST1 in the pathogenesis of vascular disorders [7–9]. Genome-wide association study has identified TWIST1 as a causal gene for common vascular diseases [7]. Mahmoud and colleagues reported that blood flow-induced shear stress increases TWIST expression and subsequently promotes vascular abnormality by inducing endothelial cell proliferation and inflammation [8]. In our recent study, SMC-specific depletion of TWIST1 protected against pulmonary vascular remodeling, thus implicating a detrimental role of TWIST1 in both systemic and pulmonary circuits [9].

Despite human studies and functional animal experiments, little information is presently available regarding its role in SMC homeostasis. As one of the pernicious transcriptional regulators involved in cellular differentiation, we hypothesized that TWIST1 might contribute to SMC transition therefore exerts promitory effects on cell misbehavior and vascular disease development. In this study, we identified TWIST1, whose expression is greatly increased in dedifferentiated/synthetic SMCs, as a novel modulator of SMC phenotypic switching via downregulation of p68 and microRNA-143/145.

Materials and methods
Details of materials and experimental procedures are available in the Supporting Information.

Animal experiment
All animal experiments were approved by Animal Care and Use Committee of Third Military Medical University. Male Sprague-Dawley rats weighing 220 to 250 g were used in these experiments, as previously described [10]. They were anesthetized by the intraperitoneal injection of 1% pentobarbital sodium (Sigma-Aldrich, St. Louis, MO, USA, 5 mg/100 g body weight). After the rats were anesthetized, the left common carotid arteries were carefully exposed through a midline cervical incision. Blood flow transiently stopped by occluding the arteries with vascular clamps, and then, a small arteriotomy was made around the external carotid artery. Afterward, the vessels were completely injured near the carotid bifurcation using a balloon embolectomy catheter (1.5F, Cordis, Miami Lakes, FL) through the incision hole. Once injured, the wounded skin was closed with a single suture. The rats were carefully looked after in the Animal Center of Third Military Medical University. The rats were sacrificed at indicated time points with intraperitoneal injection of 1% pentobarbital sodium (30mg/100 g body weight). Anesthesia was monitored by assessment of pain and corneal reflexes. Isolation of the carotid arteries was started after both reflexes completely disappeared. The carotid arteries were obtained and cleaned for the predesigned assays. Carotid arteries from sham-operated rats served as control.

Cell culture
Human aortic SMCs were purchased from the American Type Culture Collection (Manassas, VA, USA). Cells were cultured in F12 Kaighn’s medium (HyClone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, Grand Island, NY, USA). SMCs were used at passages 3 through 7.

Real-time polymerase chain reaction (PCR)
Total RNA was extracted from tissues and confluent SMCs with TRIZol reagent (TaKaRa, Tokyo, Japan) following the manufacturer’s protocol. The RNA (1000 nmol) was then subjected to reverse transcription using the PrimeScript RT reagent Kit with gDNA Eraser (TaKaRa). Afterward, SYBR Green (TaKaRa)-based real-time PCR was carried out by Applied Biosystems 7500 real-time PCR system (Applied Biosystems, Foster City, CA). Real-time PCR was performed in 20uL reactions with 10 pmol primers produced by Shangon Biotech (Shanghai, China), and the relative quantitative analysis of the change in expression levels was obtained using the comparative Ct method and normalized to the corresponding control. The specific sequences of the primers used were listed in Table 1.

Western blot analysis
SMCs were washed twice with precold PBS and harvested on ice in RIPA (Beyotime, Wuhan, China) supplemented with 1% phenylmethysulfonyl fluoride (Beyotime). All tissue samples were frozen with liquid nitrogen and homogenized,
and then lysed as previously described. The whole protein samples were diluted with 5× SDS/PAGE loading buffer and boiled 5 min. Equal amounts of protein were loaded on SDS/PAGE gels. Constant voltage was used in this step (120V running, 80V stacking). Then, proteins were transferred onto a polyvinylidene difluoride membrane (PVDF, Millipore, Etten-Leur, Netherlands) by electroblotting at constant electronic of 150 mA, followed by blocking with 5% bovine serum albumin (BSA) (Boster, Wuhan, China) for 1 h at room temperature. The membranes were incubated in their primary antibodies overnight at 4 °C (Table 2, Dilutions: antibodies against TWIST1 [1:300], SMMHC [1:500], SMA [1:1000], calponin [1:1000], tagln [1:1000], GAPDH [1:500], p68 [1:1000], and β-actin [1:1000]). The following day, the blots were washed five times (3 min per time) with Tris-Buffered Saline with Tween-20 (Beyotime); signals were detected by appropriate secondary horseradish peroxidase-conjugated antibodies (1:5000) (Abcam, Cambridge, MA, USA) for 1 h at room temperature, and visualized via enhanced chemiluminescence (Amersham International, Buckinghamshire, UK). Optical density of bands was quantified by Quantity One software and normalized with loading control.

### Table 1. Specific sequences of the primers

| Primer name | Primer sequences | Annealing temperature/fragment size | Corresponding reference RNA |
|-------------|------------------|------------------------------------|-----------------------------|
| miR-143     | For: ssD809230846 Rev: ssD809261711 (RiboBio Co., Ltd) | 60°C/78bp | U6 |
| miR-145     | For: ssD8092321411 Rev: ssD809261711 (RiboBio Co., Ltd) | 60°C/81bp | U6 |
| U6          | For: ssD904071006 Rev: ssD904071007 (RiboBio Co., Ltd) | 60°C/76bp | - |
| p68         | For: 5′-GCCACGCACAGAGGGTGAA-3′ Rev: 5′-TCCCTGAGCTTGAATAGCAGT-3′ | 60°C/170bp | β-actin |
| β-actin     | For: 5′-GACTTAGTTGCTTACACCTTCTTT-3′ Rev: 5′-TGTCACCTCACCCTTGACT-3′ | 60°C/157bp | - |

### Table 2. Antibodies for immunoblot analyses

| Antibody | Manufacturer | Catalog | Source of species | MW (kDa) |
|----------|--------------|---------|------------------|----------|
| TWIST1   | CST          | 46702   | rabbit           | 26       |
| β-actin  | Boster       | BM0627  | mouse            | 42       |
| SMMHC    | PROTEINTECH  | 21404-1-AP | rabbit        | 200      |
| SMA      | ABCAM        | Ab7817  | mouse            | 42       |
| calponin | PROTEINTECH  | 13939-1-AP | rabbit        | 33       |
| tagln    | PROTEINTECH  | 10493-1-AP | rabbit        | 22       |
| GAPDH    | CST          | 5174S   | rabbit           | 37       |
| p68      | CST          | 9877    | rabbit           | 68       |

### Lentivirus production and transfection

Lentivirus-TWIST1 siRNA and control lentivirus carrying green fluorescence protein (GFP) were produced by Invitrogen (Carlsbad, CA, USA). TWIST1 overexpressed lentivirus and the corresponding GFP control were obtained from GeneChem (Shanghai, China), p68 siRNA and the corresponding GFP control were obtained from Hanbio Biotechnology. SMCs were seeded in 24-well plate at a density of 1.9×10⁵ cells/well 24 h prior to infection. After rinsing with PBS, the lentivirus and the corresponding controls, mixed in F12K, were added into SMCs, supplemented with 0.5% polybrene. Twenty-four hours later, the medium was replaced with fresh complete growth media, and the transfection efficiency was measured by detecting GFP expression under fluorescence microscope. The transfection efficiency of more than 95% was regarded as successful. Real-time RT-PCR and western blot were further used to confirm the results of the transfection.

### Immunofluorescence

SMCs were seeded onto coverslips in 6-well plates for 24hrs prior to serum starvation (approximately 5×10⁵ cells/well). SMCs on the coverslips were fixed with 4% ice-cold paraformaldehyde for 15 min at room temperature, permeabilized with 0.5% Triton X-100, and rinsed with PBS. After washing with PBS for three times, the cells were blocked with 5% BSA for 20 min. The sections were first incubated with anti-TWIST1 antibody overnight at 4 °C. Then, secondary FITC-conjugated antibody was added. For detection of cytoskeleton remodeling, rhodamine phalloidin was used to stain F-actin. In all immunofluorescence-based assays, the nuclei were counterstained with 4',6-diamidino-2-phenylindole (DAPI). The stained cells were visualized with an Olympus confocal microscope. For immunofluorescence analysis of vessels, after deparaffinization, tissue samples were permeabilized with 1% Triton.
X-100 and then blocked with 5% BSA for 20 min, at last, with primary antibodies against TWIST1 and SMA in PBS overnight at 4 °C. Secondary antibodies were incubated for 1 h at room temperature.

Co-immunoprecipitation

The whole protein extracts of SMCs were prepared using the special lysis buffer (Cell Signaling Technology no. #9803, Danvers, MA, USA) for immunoprecipitation. The lysates were centrifuged, and protein concentrations were measured (BCA kit) and immunoprecipitated at 4°C by gently rocking overnight with the protein A/G magnetic beads (Cell Signaling Technology) prebound to anti-TWIST1 or anti-p68 antibodies prior to bind with the immunoprecipitates. Precipitated proteins were washed 5 times with PBS, boiled in 2 x sample loading buffer, and separated by 12% SDS/PAGE. The separated protein was then transferred to PVDF membrane and immunoblotted with anti-TWIST1 or anti-p68 antibody, respectively. Rabbit normal IgG (Cell Signaling Technology) served as negative control.

Statistical analysis

All data are expressed as mean ± SEM from three or more independent experiments and analyzed with PASW Statistic 21 (SPSS Inc., Chicago, IL, USA). Data between two groups were compared using two-tailed Student’s t-test. Multiple comparisons utilized one-way ANOVA followed by Student–Newman–Keuls test. P < 0.05 was considered as significant difference.

Results

Association of TWIST1 and SMC phenotypic switching

To determine whether TWIST1 is involved in smooth muscle phenotypic modulation, we evaluated its expression in the vessels from the rat carotid injury model. As shown in Figure 1A, TWIST1 staining was increased in the media region of the pathological vessels, which was associated with suppressed SMC differentiation marker—SMA, as compared with control vessels. Accordingly, western blot confirmed a significant upregulation of TWIST1 protein in the injured arteries, suggesting a negative correlation between TWIST1- and SMC-specific markers in vivo (Figure 1B).

To further verify the above observations in vitro, cultured human aortic SMCs were stimulated with platelet-derived growth factor (PDGF)-BB, which is a widely used approach for SMC differentiation study (Figure S1). The reduced expression of smooth muscle

Fig. 1. TWIST1 expression is increased in the blood vessels in neointimal injury model. (A) Phase and immunofluorescence confocal images revealed TWIST1 (red) expression in control and injured rat carotid arteries. Anti-SMA staining for SMA (green). Cell nuclei were stained with DAPI (blue). Scale bar = 20 μm. (B) western blots of TWIST1 from sham-operated vessels and balloon-injured carotid arteries at 7 and 14 days after operation, *P < 0.05 vs control, #P < 0.05 vs injured 1 week. Statistical analysis was performed using one-way ANOVA followed by Student–Newman–Keuls test. Data were reported as the mean ± SEM
markers (SMMHC, SMA, calponin, and tagln) confirmed SMC phenotypic switching due to PDGF-BB treatment. As shown in Fig. 2A, B, PDGF-BB both dose- and time-dependently enhanced TWIST1 expression in human vascular SMCs. Similarly, we observed an increase in TWIST1 level in PDGF-BB-induced dedifferentiated/synthetic SMCs, as evidenced by the morphological and cytoskeletal alternation. 

Fig. 2. TWIST1 level is elevated in dedifferentiated/synthetic SMCs. (A) Representative western blot of TWIST1 protein in SMCs challenged with different concentrations of PDGF-BB. *P < 0.05 vs control, †P < 0.05 vs 25ng·mL⁻¹ PDGF-BB. Cell lysates were obtained at indicated time points and probed with antibodies against TWIST1. *P < 0.05 vs 0 h, †P < 0.05 vs 12 h. (C) Phase and immunofluorescence confocal images revealed the effects of 25ng·mL⁻¹ PDGF-BB incubation on TWIST1 (red) expression in SMCs. Rhodamine phalloidin for F-actin (green). Cell nuclei were stained with DAPI (blue). Scale bar = 20 μm. Statistical analyses were performed using one-way ANOVA followed by Student–Newman–Keuls test. Data were reported as the mean ± SEM.
Therefore, the data suggest that TWIST1 is closely associated with the expression of smooth muscle markers during SMC phenotypic switching.

**TWIST1 induces phenotypic switching of SMC**

In an attempt to identify the potential role of TWIST1 in SMC phenotypic switching, specific small interfering RNA (siRNA) was used to knockdown TWIST1 in human aortic SMCs. Control cells were transfected with lentivirus containing scrambled control. We found that suppression of TWIST1 increased SMC-specific markers, as evaluated by western blot (Fig. 3A). Similarly, the application of harmine, a small molecular inhibitor targeting TWIST1, significantly enhanced SMC marker protein expressions (Fig. 3B).

Next, we examined the effects of TWIST1 overexpression on SMC homeostasis. For these experiments, lentivirus containing GFP or TWIST1-GFP constructs was applied. We showed that enforced TWIST1 expression strongly suppressed the expressions of SMC contractile proteins (Fig. 3C). Accordingly, TWIST1 siRNA promoted a spindle-like cell shape, while overexpression induced significant morphological change in human vascular SMCs (Fig. 3D,E). Thus, these results further support TWIST1 as being an important regulator of SMC phenotypic transition.

**MicroRNA-143/145 expression in SMCs is repressed by TWIST1**

After observing the suppressive effects of TWIST1 on smooth muscle proteins, we attempted to explore the potential mechanisms involved. Although prior study suggested the potential binding sites for bHLH proteins within SMA promoter regions, our bioinformatic search indicated no direct interaction between TWIST1 and the promoters of other SMC differentiation marker genes (http://cistrome.org/db/#/)\(^1\). MicroRNAs, modulating various biological processes by inducing target mRNA degradation or blocking translation, have been recently proved as potent regulators of SMC differentiation and biological behavior [11–13]. MicroRNA-143/145 is one of the first identified microRNA clusters participating in the phenotypic modulation of SMC; thus, we wondered whether it is involved in the process of TWIST1-induced SMC phenotypic switching [14,15]. Prior studies have shown significantly reduced microRNA-143/145 expression in SMCs from injured arteries, while overexpression of microRNA-143/145 is sufficient to promote differentiation and inhibit proliferation of SMCs [15,16]. Of note, we found that TWIST1 downregulation led to prominent increase in microRNA-143/145 in SMCs, as compared with control (Fig. 4A). In contrast, enforced TWIST1 expression significantly repressed microRNA-143/145 level (Fig. 4B).

Our previous study showed that p68 is pivotal for maintaining the contractile phenotype of SMCs, which is also one of the major proteins responsible for the canonical microRNA biogenesis [10]. Similar to the prior microRNA-143/145 report, the expression of p68 was decreased in smooth muscle of the pathological vessels (Fig. S2). To determine whether p68 is involved in the negative regulation of SMC phenotype and microRNA-143/145 by TWIST1, we first examined the potential impacts of TWIST1 on p68 expression (Fig. 4C,D). The data showed that knockdown of TWIST1 efficiently improved p68 mRNA level in SMCs, whereas lentivirus-mediated enforced expression of TWIST1 markedly repressed p68. Although TWIST1 is known as a transcription factor, the chip-sequencing datasets revealed no close interaction between TWIST1 and the promoter of p68, indicating a potentially indirect inhibition of p68 mRNA level (http://cistrome.org/db/#/). In agreement with the findings from the mRNA study, western blots confirmed a negative correlation between TWIST1 and p68 (Fig. 4E,F). Furthermore, we found that p68 knockdown markedly reduced microRNA-143/145 expression (Fig. 4G). Based on the results, we speculated upon the possibility of p68 protein as a downstream mediator of TWIST1-induced suppression of microRNA-143/145 and SMC transition.

**TWIST1 suppresses microRNA-143/145 in a p68-dependent manner**

To further verify the potential link between TWIST1 and p68, we performed co-immunoprecipitation assay using the detergent extracts prepared from human aortic SMCs. As shown in Fig. 5A, western blot analysis of immunoprecipitates demonstrated a specific p68 band brought down by TWIST1 antibody, but not by control IgG. In accordance with this observation, co-immunoprecipitation with anti-p68 antibody revealed that p68 also precipitated TWIST1. Thus, TWIST1 was capable of binding to p68. Prior study showed that TWIST1 could regulate the activity of proteasome system [17]. Thus, the proteasome inhibitor MG132 was applied to determine whether the inhibitory effect of TWIST1 on p68 was proteasome-mediated. We demonstrated that suppression of p68 protein by TWIST1 overexpression in SMCs was partially blocked at the presence of MG132, indicating that...
Fig. 3. TWIST1 induces SMC phenotypic switching. (A) Protein levels of SMMHC, SMA, calponin, and tagln in SMCs transfected with scrambled or TWIST1-specific siRNA. *P < 0.05. (B) SMCs were treated with either vehicle or harmine for 24hrs. Expression of SMMHC, SMA, calponin, and tagln protein was measured by western blot. *P < 0.05. (C) Representative immunoblots of SMMHC, SMA, calponin, and tagln protein expression in control or TWIST1 overexpressing SMCs. *P < 0.05. (D) and (E) Immunofluorescence confocal images revealed F-actin (red) in SMC transfected with TWIST1-specific siRNA (D) and TWIST1 virus (E). Cell nuclei were stained with DAPI (blue). Scale bar = 20 µm. Statistical analyses were performed using two-tailed Student’s t-test. Data were reported as the mean ± SEM.
TWIST1 might directly target p68 and promote its proteasomal degradation (Fig. S3).

To further assess the contribution of p68 to the negative role of TWIST1 in SMC differentiation, we transfected SMCs with TWIST1 siRNA lentivirus plus either scrambled or p68 siRNA lentivirus. Importantly, we found that knockdown of p68 abolished the protective effects of TWIST1 depletion on SMC homeostasis, as evidenced by western blot and immunofluorescence staining (Fig. 5B,C). In accordance with the SMC phenotype study, transfection of p68 siRNA lentivirus but not scrambled control largely inhibited TWIST1 silencing-induced elevation of microRNA-143/145 level, suggesting that TWIST1-guided regulation of SMC transition and microRNA-143/145 expression might be mediated by p68 (Fig. 5D). Taken together, our data present evidence that TWIST1-induced SMC phenotypic switching is attributable to inhibition of p68-dependent microRNA-143/145 expression.

**Discussion**

Although prior studies have indicated a role of TWIST1 in vascular disease and endothelial function, its contribution to SMC transition remains unclear. To our knowledge, this is the first study demonstrating...
TWIST1 and smooth muscle cell phenotype

J. Zhang et al.

A

[Image: Immunoprecipitation (IP) and Western Blot (WB) analysis showing protein expression.

B

[Table: Protein expression levels and siRNA effects on protein expression.

C

[Images: F-actin/DAPI staining for scrambled siRNA, TWIST1 siRNA, and TWIST1 siRNA + p68 siRNA.

D

[Bar graphs: Relative miR-143 and miR-145 expression levels for different siRNA treatments.

Scrambled siRNA
TWIST1 siRNA
Scrambled siRNA + p68 siRNA

FEBS Open Bio 11 (2021) 932–943 © 2021 The Authors. FEBS Open Bio published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
that TWIST1, a key regulator of endothelial/epithelial to mesenchymal transition, promoted SMC phenotypic switching that is necessarily required for the development of multiple vascular abnormalities, and intimately linked with SMC behavior and function. The underlying mechanism of this process is that TWIST1 directly binds to p68 protein and decreases its expression. TWIST1 downregulates microRNA-143/145 expression through repressing p68, which is the molecular key to switch the phenotype of SMCs. Overall, the data showed a previously unknown role of TWIST1 in SMC homeostasis regulation.

TWIST1, a critical embryonic transcription factor, was initially discovered in Drosophila and extremely important for the early development of mesoderm formation [18,19]. It belongs to the basic helix-loop-helix transcription factor family, which plays significant roles in various physiological and pathophysiological processes. In humans, TWIST1 mutation leads to Saethre-Chotzen syndrome, a genetic disorder characterized by the premature fusion of certain skull bones. TWIST1 is well-known for its essential role in tumor development, metastasis, and chemoresistance in a variety of cancers [20,21]. Intriguingly, recent evidence suggests TWIST1 acting as a crucial mediator of arterial disease development and vascular cell misbehavior [7–9].

In spite of the efforts evaluating the contributions of TWIST1 to vascular angiogenesis and pathogenesis, most of them payed their attentions to its proproliferative property, and little information is currently available regarding its effects on SMC homeostasis that is the basis for the development and progression of various arterial disorders. Besides, despite the close relationships between TWIST1 and a wide range of arterial abnormalities, a universal interpretation of its extensive and detrimental effects in the world of vascular disease is absence. Therefore, we first determined the change in TWIST1 expression during SMC phenotypic transition, which showed a markedly elevated TWIST1 level in both injured rat carotid artery and PDGF-BB-treated dedifferentiated/synthetic SMCs. Importantly, inhibition of TWIST1 through either specific siRNA or pharmacological inhibitor prevented SMC phenotypic switching. Likewise, overexpression of TWIST1 resulted in the transition of SMCs to a synthetic state, thus reinforced the role of TWIST1 in SMC phenotypic switching, and made us to further explore the mechanism involved.

Loss of smooth muscle markers is the hallmark of SMC phenotypic switching. As an important regulator of targeted gene transcription, TWIST1 has been shown to inhibit SMA expression by binding to and inactivating SMA promoter [22]. However, our ChIP-sequencing database search revealed no direct interplay between TWIST1 and the promoters of other SMC differentiation markers; thus, its transcription regulatory property might not fully explain the universal suppressive effects of TWIST1 on smooth muscle genes. MicroRNAs have recently received much attention for their ability in tempering gene expression [23–25]. In particular, they can act as crucial modulators of SMC phenotypic transition and proliferation [26,27]. Several microRNAs, including microRNA-143/145, microRNA-663, and microRNA-133, have a demonstrated role in SMC phenotypic change [28–30]. Notably, we showed that TWIST1 inhibition increased microRNA-143/145 expression, while overexpression of TWIST1 downregulated its level, indicating that the function of TWIST1 on SMC plasticity might be mediated by microRNA-143/145.

In delineating how TWIST1 triggered SMC transition and repressed microRNA-143/145, we focused our attention on p68, a prototypic member of the DEAD box family that is a vital regulator of both SMC differentiation and microRNA processing [31]. The present study showed that TWIST1 overexpression inhibited p68 protein and mRNA levels, while TWIST1 inhibition recruited PDGF-BB-induced downregulation of p68 expression. In addition, knockdown of p68 significantly decreased microRNA-143/145, which is in accordance with previous reports demonstrating its potent capacity in regulating microRNA [32]. Although TWIST1 is known for its transcription regulatory capacity, no evidences support the interaction between TWIST1 and p68 promoter, thus implicating a potentially indirect regulation of p68 mRNA level. The co-immunoprecipitation experiment
revealed a de novo interplay between TWIST1 and p68. In addition, the data suggested that TWIST1 induces the proteasomal degradation of p68. Thus, TWIST1 might be a molecular partner of p68 and directly impact its expression and biological function, which leads to SMC transition. Importantly, transfection of p68 siRNA inhibited the protective effects of TWIST1 inhibition on SMC phenotypic switching and microRNA-143/145 expression, implying that TWIST1-induced SMC phenotypic modulation is, at least partially, through downregulation of microRNA-143/145 via repressing p68.

Limitation
Our study has several limitations. First, the in vitro study could be biased by the switch of SMCs from the contractile to synthetic phenotype when they were passaged. However, we have tried our best to use SMC from the same passage in each experiment, which might reduce this bias. Second, there were no relevant animal experiments assessing the impacts of TWIST1 on SMC phenotypic switching. The in vivo regulatory effects of TWIST1 on SMC homeostasis still need further research.

Conclusions
In conclusion, our work defines a previously unreported role of TWIST1 in modulating SMC differentiation, through a novel mechanism that it inhibits microRNA-143/145 in a p68-dependent manner. TWIST1 might be a potential therapeutic target in phenotype-related vascular disorders.

Acknowledgements
This work was supported by the National Natural Science Foundation of the People’s Republic of China (81873414).

Conflicts of interest
The authors declare no conflict of interest.

Author contributions
JZ and JRG contributed equally to this study. YW, XG, and YF designed the experiments. JZ, JRG, and XLW performed the experiments. XW analyzed data. YF wrote the manuscript. XG and YF made manuscript revisions. YW supervised the study.

Data Availability Statement
The data are available from the corresponding author upon reasonable request.

References
1 Murgai M, Ju W, Eason M, Kline J, Beury DW, Kaczanowska S, Miettinen MM, Kruhlak M, Lei H, Shern JF et al, (2017) KLF4-dependent perivascular cell plasticity mediates pre-metastatic niche formation and metastasis. Nat Med 23, 1176–1190.
2 Fan Y, Zhang J, Chen CY, Xiao YB, Asico LD, Jose PA, Xu JC, Qian GS and Zeng CY (2017) Macrophage migration inhibitory factor triggers vascular smooth muscle cell dedifferentiation by a p68-serum response factor axis. Cardiovasc Res 113, 519–530.
3 Shi JH, Zheng B, Li YH, Sun Y, Han AL, Zhang XH, Lv XR, Chen S and Wen JK (2013) Novel insight into Y-box binding protein 1 in the regulation of vascular smooth muscle cell proliferation through targeting GC box-dependent genes. FEBS Lett 587, 1326–1332.
4 Zhao G, Fu Y, Cai Z, Yu F, Gong Z, Dai R, Hu Y, Zeng L, Xu Q and Kong W (2017) Unspliced XBP1 confers VSMC homeostasis and prevents aortic aneurysm formation via FoxO4 interaction. Circ Res 121, 1331–1345.
5 Harper KL, Sosa MS, Entenberg D, Hosseini H, Cheung JF, Nobre R, Avivar-Valderas A, Nagi C, Girmius N, Davis RJ et al, (2016) Mechanism of early dissemination and metastasis in Her2+ mammary cancer. Nature 540, 588–592.
6 van Doorn R, Dijkman R, Vermeer MH, Out-Luiting JJ, van der Raaij-Helmer EM, Willemze R and Tensen CP (2004) Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in S é zary syndrome identified by gene expression analysis. Cancer Res 64, 5578–5586.
7 Nurnberg ST, Guerraty MA, Wirka RC, Rao HS, Pjanic M, Norton S, Serrano F, Perisic L, Elwyn S, Pluta J et al, (2020) Genomic profiling of human vascular cells identifies TWIST1 as a causal gene for common vascular diseases. PLoS Genet 16, e1008538.
8 Mahmoud MM, Kim HR, Xing R, Hsiao S, Mammoto A, Chen J, Serbanovic-Canic J, Feng S, Bowden NP, Maguire R et al, (2016) TWIST1 integrates endothelial responses to flow in vascular dysfunction and atherosclerosis. Circ Res 120, 450–462.
9 Fan Y, Gu X, Zhang J, Sinn K, Klepetko W, Wu N, Foris V, Solymosi P, Kwapiowszewska G and Kuebler WM. (2020) TWIST1 Drives Smooth Muscle Cell Proliferation in Pulmonary Hypertension via Loss of GATA-6 and BMPR2. Am J Respir Crit Care Med 202, 1283–1296.
10 Fan Y, Chen Y, Zhang J, Yang F, Hu Y, Zhang L, Zeng C and Xu Q (2019) Protective role of RNA helicase DEAD-Box protein 5 in smooth muscle cell proliferation and vascular remodeling. *Circ Res* 124, e84–e100.

11 Lu Y, Thavarajah T, Gu W, Cai J and Xu Q (2018) Impact of miRNA in atherosclerosis. *Arterioscler Thromb Vasc Biol* 38, e159–e170.

12 Maegdefessel L, Rayner KJ and Leeper NJ (2015) MicroRNA regulation of vascular smooth muscle function and phenotype: early career committee contribution. *Arterioscler Thromb Vasc Biol* 35, 2–6.

13 Kang H and Hata A (2012) MicroRNA regulation of smooth muscle gene expression and phenotype. *Curr Opin Hematol* 19, 224–231.

14 Rangrez AY, Massy ZA, Metzinger-Le Meuth V and Metzinger L (2011) miR-143 and miR-145: molecular keys to switch the phenotype of vascular smooth muscle cells. *Circ Cardiovasc Genet* 4, 197–205.

15 Zhao W, Zhao SP and Zhao YH (2015) MicroRNA-143/-145 in Cardiovascular diseases. *Biomed Res Int* 2015, 531740.

16 Cheng Y, Liu X, Yang J, Lin Y, Xu DZ, Lu Q, Deitch EA, Huo Y, Delphin ES and Zhang C (2009) MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. *Circ Res* 105, 158–166.

17 Baumgarten A, Bang C, Tschirner A, Engelmann A, Adams V, von Haelpling S, Doehner W, Pregla R, Anker MS, Blecharz K *et al.*, (2013) TWIST1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy. *Int J Cardiol* 168, 1447–1452.

18 Simpson P (1983) Maternal-Zygotic gene interactions during formation of the dorsoventral pattern in Drosophila embryos. *Genetics* 105, 615–632.

19 Fäthtbauer EM (1995) Expression of M-twist during postimplantation development of the mouse. *Dev Dyn* 204, 316–322.

20 Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, Wu CC, LeBlou VS and Kalluri R (2015) Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. *Nature* 527, 525–530.

21 Ma L, Teruya-Feldstein J and Weinberg RA (2007) Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. *Nature* 449, 682–688.

22 Kumar MS, Hendrix JA, Johnson AD and Owens GK (2003) Smooth muscle alpha-actin gene requires two E-boxes for proper expression in vivo and is a target of class I basic helix-loop-helix proteins. *Circ Res* 92, 840–847.

23 Small EM and Olson EN (2011) Pervasive roles of microRNAs in cardiovascular biology. *Nature* 469, 336–342.

24 Small EM, Frost RJ and Olson EN (2010) MicroRNAs add a new dimension to cardiovascular disease. *Circulation* 121, 1022–1032.

25 Lekka E and Hall J (2018) Noncoding RNAs in disease. *FEBS Lett* 592, 2884–2900.

26 Zeng Y, Pan Y, Liu H, Kang K, Wu Y, Hui G, Peng W, Ramchandran R, Raj JU and Gou D (2014) MiR-20a regulates the PRKG1 gene by targeting its coding region in pulmonary arterial smooth muscle cells. *FEBS Lett* 588, 4677–4685.

27 Kee HJ, Park S, Kwon JS, Choe N, Ahn Y, Kook H and Jeong MH (2013) B cell translocation gene, a direct target of miR-142-5p, inhibits vascular smooth muscle cell proliferation by down-regulating cell cycle progression. *FEBS Lett* 587, 2385–2392.

28 Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, Lee TH, Miano JM, Ivey KN and Srivastava D (2009) miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. *Nature* 460, 705–710.

29 Li P, Zhu N, Yi B, Wang N, Chen M, You X, Zhao X, Solomides CC, Qin Y and Sun J (2013) MicroRNA-663 regulates human vascular smooth muscle cell phenotypic switch and vascular neointimal formation. *Circ Res* 113, 1117–1127.

30 Torella D, Iaconetti C, Catalucci D, Ellison GM, Leone A, Waring CD, Bochicchio A, Vicinanza C, Aquila I, Curcio A *et al.*, (2011) MicroRNA-133 controls vascular smooth muscle cell phenotypic switch in vitro and vascular remodeling in vivo. *Circ Res* 109, 880–893.

31 Davis BN, Hilyard AC, Lagna G and Hata A (2008) SMAD proteins control DROSHA-mediated microRNA maturation. *Nature* 454, 56–61.

32 Fuller-Pace FV and Moore HC (2011) RNA helicases p68 and p72: multifunctional proteins with important implications for cancer development. *Future Oncol* 7, 239–251.

**Supporting information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Fig S1.** Representative Western blot of SMMHC, SMA, calponin, tagln expression in SMCs treated with 25ng/ml PDGF (platelet-derived growth factor)-BB. Statistical analyses were performed using two-tailed Student’s t test.

**Fig S2.** Phase and immunofluorescence confocal images revealed p68 (red) expression in control and injured rat carotid arteries.